Literature DB >> 3807996

Predeposited autologous blood for elective surgery. A national multicenter study.

P T Toy, R G Strauss, L C Stehling, R Sears, T H Price, E C Rossi, M L Collins, J P Crowley, R S Eisenstaedt, L T Goodnough.   

Abstract

To determine the extent to which autologous blood that has been donated in advance ("predeposited") is used in patients undergoing elective surgery and to assess whether predonation decreases the use of homologous blood and the demand on the blood supply, we studied 4996 patients undergoing elective surgery at 18 tertiary care hospitals. Cross-matched blood was ordered for 1287 patients (26 percent), and of these, 590 (46 percent) were considered eligible for predepositing blood. Only 5 percent (32) of the eligible patients actually predeposited blood, indicating that predonation is not widely used. Of those who predeposited, only 13 percent (4 of 32) subsequently received homologous blood, as compared with 36 percent (199 of 558) of those who did not predeposit (P less than 0.01). Among the 199 patients who did not predeposit but required transfusion, we estimate that predonation could have avoided homologous transfusion in as many as 68 percent. If all eligible patients had predeposited autologous blood, they could have supplied as much as 72 percent of their own transfused red cells. The blood for as much as 10 percent of all red-cell transfusions could have been predonated by and transfused into the patients undergoing elective surgery. Greater use of predonation would not only reduce the demand on the blood supply by decreasing the need for homologous transfusion, but would probably also reduce the risk of hepatitis and other transfusion-associated illnesses.

Entities:  

Mesh:

Year:  1987        PMID: 3807996     DOI: 10.1056/NEJM198702263160906

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  10 in total

1.  Efficiency of blood use and prospects for autologous transfusion in general surgery.

Authors:  B Jaffray; P M King; M M Basheer; J Gillon
Journal:  Ann R Coll Surg Engl       Date:  1991-07       Impact factor: 1.891

Review 2.  A risk-benefit assessment of aprotinin in cardiac surgical procedures.

Authors:  W B Dobkowski; J M Murkin
Journal:  Drug Saf       Date:  1998-01       Impact factor: 5.606

Review 3.  [Blood-saving procedures--anesthesiologic aspects. Autotransfusion procedures at a large clinic].

Authors:  B von Bormann
Journal:  Unfallchirurgie       Date:  1989-08

4.  Autologous blood collection in anemic patients using low-dose erythropoietin therapy.

Authors:  L S Mott; J Bechinski; M J Jones
Journal:  J Natl Med Assoc       Date:  1997-06       Impact factor: 1.798

5.  Effect of perioperative blood transfusion on clinical outcomes in hepatic surgery for cancer.

Authors:  Gianlorenzo Dionigi; Luigi Boni; Francesca Rovera; Stefano Rausei; Salvatore Cuffari; Giovanni Cantone; Alessandro Bacuzzi; Renzo Dionigi
Journal:  World J Gastroenterol       Date:  2009-08-28       Impact factor: 5.742

Review 6.  Limiting excessive postoperative blood transfusion after cardiac procedures. A review.

Authors:  V A Ferraris; S P Ferraris
Journal:  Tex Heart Inst J       Date:  1995

7.  Regional transfusion centre preoperative autologous blood donation programme: the first two years.

Authors:  M R Howard; C E Chapman; J A Dunstan; C Mitchell; H L Lloyd
Journal:  BMJ       Date:  1992-12-12

8.  Autologous blood donation in a small general acute-care hospital.

Authors:  L S Mott; M J Jones
Journal:  J Natl Med Assoc       Date:  1995-08       Impact factor: 1.798

9.  Autologous deposit of blood by oncology patients: an evaluation of actual use and wastage.

Authors:  S P Shaheen; B Lichtiger
Journal:  Ann Surg Oncol       Date:  1995-09       Impact factor: 5.344

10.  Technetium-99m-labeled autologous serum albumin: a personal-exclusive source of serum component.

Authors:  Yuh-Feng Wang; Yi-Chun Chen; Dian-Kun Li; Mei-Hua Chuang
Journal:  J Biomed Biotechnol       Date:  2011-04-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.